知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.014 seconds)

    IL1-R1 derived inhibitor of IL-1β and use thereof
    1.
    发明授权
    IL1-R1 derived inhibitor of IL-1β and use thereof 有权

    公开(公告)号：US12180264B2

    公开(公告)日：2024-12-31

    申请号：US17474718

    申请日：2021-09-14

    Applicant: R-Pharm Overseas, Inc.

    Inventor： Yan Lavrovsky ,  Alexey Repik ,  Mikhail Samsonov ,  Sergei Barbashov ,  Vasily Ignatiev

    IPC: C07K14/715 ,  A61K38/00

    Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1β. In certain aspects, the disclosed composition is based on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1β and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.

    IL1-R1 DERIVED INHIBITOR OF IL-1b AND USE THEREOF
    2.
    发明申请
    IL1-R1 DERIVED INHIBITOR OF IL-1b AND USE THEREOF 有权

    公开(公告)号：US20210403534A1

    公开(公告)日：2021-12-30

    申请号：US17474718

    申请日：2021-09-14

    Applicant: R-Pharm Overseas, Inc.

    Inventor： Yan Lavrovsky ,  Alexey Repik ,  Mikhail Samsonov ,  Sergei BARBASHOV ,  Vasily IGNATIEV

    IPC: C07K14/715

    Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1β. In certain aspects, the disclosed composition is based on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1β and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.

    Human IL1-R1 Derived Inhibitor of IL-1b
    4.
    发明申请
    Human IL1-R1 Derived Inhibitor of IL-1b 审中-公开

    公开(公告)号：US20170226185A1

    公开(公告)日：2017-08-10

    申请号：US15129412

    申请日：2014-03-24

    Applicant: R-Pharm Overseas, Inc.

    Inventor： Yan Lavrovsky ,  Ting Xu ,  Elena Batienko ,  Anna Krotkova ,  Vasily Ignatiev ,  Mikhail Samsonov ,  Alexey Repik

    IPC: C07K14/715

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/1793 ,  C07K14/715 ,  C07K2319/30

    Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1β. In certain aspects, the disclosed invention is based, on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1β and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.

    Osteoprotegerin derived RANKL inhibitor
    5.
    发明申请
    Osteoprotegerin derived RANKL inhibitor 审中-公开
    骨保护素衍生的RANKL抑制剂

    公开(公告)号：US20170073391A1

    公开(公告)日：2017-03-16

    申请号：US15124026

    申请日：2014-03-06

    Applicant: R-Pharm Overseas, Inc.

    Inventor： Yan Lavrovsky ,  Ting Xu ,  Irina Kostareva ,  Shorena Archuadze ,  Vasily Ignatiev ,  Mikhail Samsonov ,  Alexey Repik

    IPC: C07K14/705

    CPC classification number: C07K14/70578 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/32

    Abstract: A pharmaceutical composition is described that can be used for treating or prevention of diseases association with bone resorption, particularly of a metastatic carcinoma. In certain aspects, the composition is based on a polypeptide which includes the leading 215 amino acids of the human osteoprotegerin followed by the Fc portion of the human IgG1 protein. Pharmaceutical formulations are provided that are suitable for administering the pharmaceutical composition into primates via subcutaneous and intravenous routes.

    Abstract translation: 描述了可用于治疗或预防与骨吸收相关的疾病，特别是转移性癌的药物组合物。 在某些方面，组合物是基于多肽，其包括人骨保护素的前导215个氨基酸，随后是人IgG1蛋白的Fc部分。 提供了适于通过皮下和静脉内途径将药物组合物施用于灵长类动物的药物制剂。

    Human IL1-R1 derived inhibitor of IL-1β
    7.
    发明授权
    Human IL1-R1 derived inhibitor of IL-1β 有权

    公开(公告)号：US11155600B2

    公开(公告)日：2021-10-26

    申请号：US15129412

    申请日：2014-03-24

    Applicant: R-Pharm Overseas, Inc.

    Inventor： Yan Lavrovsky ,  Ting Xu ,  Elena Batienko ,  Anna Krotkova ,  Vasily Ignatiev ,  Mikhail Samsonov ,  Alexey Repik

    IPC: C07K14/715 ,  A61K38/17 ,  A61K38/00

    Abstract: A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1β. In certain aspects, the disclosed invention is based, on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1β and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.

    ANTI-PD-L1 ANTIBODY AND USE THEREOF
    8.
    发明申请
    ANTI-PD-L1 ANTIBODY AND USE THEREOF 有权

    公开(公告)号：US20210115143A1

    公开(公告)日：2021-04-22

    申请号：US16606647

    申请日：2018-04-18

    Applicant: R-PHARM OVERSEAS, INC.

    Inventor： Yan LAVROVSKY ,  Ting XU ,  Sergei BARBASHOV ,  Alexey REPIK ,  Mikhail SAMSONOV ,  Vasily IGNATIEV ,  Shorena ARCHUADZE

    IPC: C07K16/28 ,  A61P35/00

    Abstract: Fully human anti-PD-L1 antibodies and their corresponding applications. Fully human antibodies capable of specifically binding to human PD-L1 were obtained by employing a yeast display library-based screening technique and also by affinity maturation to further improve their affinity for PD-L1. The fully human anti-PD-L1 antibodies show good specificity, affinity and stability. They are capable of enhancing T cell activity by binding to activated T cells, while significantly inhibiting tumor growth, and can be used in the diagnosis and treatment of PD-L1-related cancers and other associated diseases.

Patent Agency Ranking